4.4 Review

Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline

期刊

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
卷 25, 期 -, 页码 315-322

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.jgar.2021.04.006

关键词

Tigecycline; Infection; Pharmacokinetics/pharmacodynamics; PK/PD; Non-linear protein binding; Dose optimisation

资金

  1. Wu Jieping Medical Foundation [320.6750.20200429]
  2. Bethune Medical Science Foundation

向作者/读者索取更多资源

Tigecycline, a novel glycylcycline antibiotic, has shown promising efficacy against various micro-organisms, but concerns have been raised about its potential to increase all-cause mortality. Recommendations for higher dosages in treating serious infections should consider the drug's atypical protein binding property, and combination therapy with other antibiotics may help lower the MICs of multidrug-resistant bacteria.
Tigecycline, a new first-in-class glycylcycline antibiotic, has shown promising efficacy against a broad range of micro-organisms. It is widely prescribed for various infections, with most prescriptions being considered for off-label use. However, only a few years after its approval by the US Food and Drug Administration (FDA), tigecycline is suspected of increasing all-cause mortality. Some clinicians have suggested such unfavourable outcomes correlate with inadequate drug exposure at the infection site. The pharmacokinetic/pharmacodynamic (PK/PD) profile of a drug plays an important role in predicting its antibiotic effect, which for tigecycline is determined as the ratio of area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC). In this study, PK/PD targets based on infection sites, bacterial isolates and patient populations are discussed. Generally, a higher dosage of tigecycline for the treatment of serious infections has been recommended in previous reports. However, the latest finding of tigecycline's atypical protein binding property requires consideration when recommending further use. In addition, combination therapy with other antibiotics provides another option by potentially lowering the MICs of multidrug-resistant bacteria. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据